Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jan, Beroušek"'
Autor:
Martin Šíma, Daniel Bobek, Petra Cihlářová, Pavel Ryšánek, Jaroslava Roušarová, Jan Beroušek, Martin Kuchař, Tomáš Vymazal, Ondřej Slanař
Publikováno v:
Pharmaceutics, Vol 14, Iss 8, p 1627 (2022)
The objective of this prospective study was to examine the exposure to the main active metabolites of ciprofloxacin in critically ill patients and to examine the factors (demographic, laboratory and genetic) that could potentially affect the drug met
Externí odkaz:
https://doaj.org/article/76078f1e4d4b4da8bb6511313dc0fd6a
Autor:
Jakub Petrus, Tomáš Grondžák, Jana Čepová, Kateřina Dunovská, Božena Hosnedlová, Jan Beroušek, Richard Průša, René Kizek, Eva Klapková
Publikováno v:
Chemické listy. 116:687-692
One of the officially approved medications for the treatment of the pandemic disease COVID-19, caused by the SARS-CoV-2 virus, is remdesivir. This antiviral molecule is a prodrug that is metabolized into its active form (an ATP analogue). Because of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca04f7591c99ba2f196c60143a3301bf
https://doi.org/10.54779/chl20220687
https://doi.org/10.54779/chl20220687
Autor:
Martin Šíma, Danica Michaličková, Pavel Ryšánek, Petra Cihlářová, Martin Kuchař, Daniela Lžičařová, Jan Beroušek, Jan Miroslav Hartinger, Tomáš Vymazal, Ondřej Slanař
Publikováno v:
Pharmaceutics, Vol 13, Iss 8, p 1156 (2021)
The aim of this prospective PK study was to evaluate the pharmacokinetics of ciprofloxacin dosed within the first 36 h (early phase) and after 3 days of treatment (delayed phase) using individual and population PK analysis. The secondary aim of the s
Externí odkaz:
https://doaj.org/article/91486b6d3d6040918d05e6001370afb4
Autor:
Jan, Beroušek1 jan.berousek@fnmotol.cz, Karel, Cvachovec1
Publikováno v:
Anaesthesiology & Intensive Medicine / Anesteziologie a Intenzivní Medicína. Dec2011, Vol. 22 Issue 6, p343-347. 5p.